---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-036925"
form_type: "8-K"
ticker: "PTIX"
cik: "0001022899"
company_name: "Protagenic Therapeutics, Inc.new"
filed_at: "2024-09-18T23:59:59+00:00"
generated_at: "2026-05-31T03:50:23.419375+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Protagenic Therapeutics updates PT00114 milestones: Phase I multi-dose Q4 2024, Phase IIa Q3 2025

## Summary
- Multiple dose portion of Phase I study for PT00114 expected to commence Q4 2024.
- Results from multiple dose portion of Phase I study for PT00114 expected Q2 2025.
- Initiation of Phase IIa study for PT00114 expected Q3 2025.
- Company will provide further updates to clinical development schedule as it becomes clearer.

## SEC filing metadata
- accession: 0001493152-24-036925
- form_type: 8-K
- ticker: PTIX
- cik: 0001022899
- company_name: Protagenic Therapeutics, Inc.new
- filed_at: 2024-09-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1022899/000149315224036925/0001493152-24-036925-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1022899/000149315224036925/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-036925
- JSON: https://secwatch.observer/filing/0001493152-24-036925.json
- Plain text: https://secwatch.observer/filing/0001493152-24-036925.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.